Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Publication Date:
2018-08-28
Publisher:
Molecular Diversity Preservation International (MPDI)
Electronic ISSN:
2072-6694
Topics:
Medicine
Published by:
http://www.mdpi.com/
_version_ 1836399037232709632
autor Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
beschreibung Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Cancers doi: 10.3390/cancers10090293 Authors: Ana P. Santos Ana C. Santos Clara Castro Luís Raposo Sofia S. Pereira Isabel Torres Rui Henrique Helena Cardoso Mariana P. Monteiro The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several cancers even though no link with GEP-NETs was yet established. Our aim in this study was to investigate whether well-differentiated GEP-NETs were associated with obesity and MetS. Patients with well-differentiated GEP-NETs (n = 96) were cross-matched for age, gender, and district of residence with a control group (n = 96) derived from the general population in a case-control study. Patients presented gastro-intestinal (75.0%) or pancreatic (22.9%) tumors, grade G1 (66.7%) or G2 (27.1%) with localized disease (31.3%), regional metastasis (16.7%) or distant metastasis (43.8%) at diagnosis, and 45.8% had clinical hormonal syndromes. MetS was defined according to Joint Interim Statement (JIS) criteria. Well-differentiated GEP-NETs were associated with MetS criteria as well as the individual components’ waist circumference, fasting triglycerides, and fasting plasma glucose (p = 0.003, p = 0.002, p = 0.011 and p < 0.001, respectively). The likelihood of the association was higher when the number of individual MetS components was greater than four. MetS and some individual MetS components including visceral obesity, dyslipidemia, and increased fasting glucose are associated with well-differentiated GEP-NET. This data provides a novel insight in unraveling the mechanisms leading to GEP-NET disease.
citation_standardnr 6324165
datenlieferant ipn_articles
feed_id 128590
feed_publisher Molecular Diversity Preservation International (MPDI)
feed_publisher_url http://www.mdpi.com/
insertion_date 2018-08-28
journaleissn 2072-6694
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher Molecular Diversity Preservation International (MPDI)
quelle Cancers
relation http://www.mdpi.com/2072-6694/10/9/293
search_space articles
shingle_author_1 Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
shingle_author_2 Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
shingle_author_3 Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
shingle_author_4 Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
shingle_catch_all_1 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Cancers doi: 10.3390/cancers10090293 Authors: Ana P. Santos Ana C. Santos Clara Castro Luís Raposo Sofia S. Pereira Isabel Torres Rui Henrique Helena Cardoso Mariana P. Monteiro The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several cancers even though no link with GEP-NETs was yet established. Our aim in this study was to investigate whether well-differentiated GEP-NETs were associated with obesity and MetS. Patients with well-differentiated GEP-NETs (n = 96) were cross-matched for age, gender, and district of residence with a control group (n = 96) derived from the general population in a case-control study. Patients presented gastro-intestinal (75.0%) or pancreatic (22.9%) tumors, grade G1 (66.7%) or G2 (27.1%) with localized disease (31.3%), regional metastasis (16.7%) or distant metastasis (43.8%) at diagnosis, and 45.8% had clinical hormonal syndromes. MetS was defined according to Joint Interim Statement (JIS) criteria. Well-differentiated GEP-NETs were associated with MetS criteria as well as the individual components’ waist circumference, fasting triglycerides, and fasting plasma glucose (p = 0.003, p = 0.002, p = 0.011 and p < 0.001, respectively). The likelihood of the association was higher when the number of individual MetS components was greater than four. MetS and some individual MetS components including visceral obesity, dyslipidemia, and increased fasting glucose are associated with well-differentiated GEP-NET. This data provides a novel insight in unraveling the mechanisms leading to GEP-NET disease.
Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
Molecular Diversity Preservation International (MPDI)
2072-6694
20726694
shingle_catch_all_2 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Cancers doi: 10.3390/cancers10090293 Authors: Ana P. Santos Ana C. Santos Clara Castro Luís Raposo Sofia S. Pereira Isabel Torres Rui Henrique Helena Cardoso Mariana P. Monteiro The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several cancers even though no link with GEP-NETs was yet established. Our aim in this study was to investigate whether well-differentiated GEP-NETs were associated with obesity and MetS. Patients with well-differentiated GEP-NETs (n = 96) were cross-matched for age, gender, and district of residence with a control group (n = 96) derived from the general population in a case-control study. Patients presented gastro-intestinal (75.0%) or pancreatic (22.9%) tumors, grade G1 (66.7%) or G2 (27.1%) with localized disease (31.3%), regional metastasis (16.7%) or distant metastasis (43.8%) at diagnosis, and 45.8% had clinical hormonal syndromes. MetS was defined according to Joint Interim Statement (JIS) criteria. Well-differentiated GEP-NETs were associated with MetS criteria as well as the individual components’ waist circumference, fasting triglycerides, and fasting plasma glucose (p = 0.003, p = 0.002, p = 0.011 and p < 0.001, respectively). The likelihood of the association was higher when the number of individual MetS components was greater than four. MetS and some individual MetS components including visceral obesity, dyslipidemia, and increased fasting glucose are associated with well-differentiated GEP-NET. This data provides a novel insight in unraveling the mechanisms leading to GEP-NET disease.
Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
Molecular Diversity Preservation International (MPDI)
2072-6694
20726694
shingle_catch_all_3 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Cancers doi: 10.3390/cancers10090293 Authors: Ana P. Santos Ana C. Santos Clara Castro Luís Raposo Sofia S. Pereira Isabel Torres Rui Henrique Helena Cardoso Mariana P. Monteiro The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several cancers even though no link with GEP-NETs was yet established. Our aim in this study was to investigate whether well-differentiated GEP-NETs were associated with obesity and MetS. Patients with well-differentiated GEP-NETs (n = 96) were cross-matched for age, gender, and district of residence with a control group (n = 96) derived from the general population in a case-control study. Patients presented gastro-intestinal (75.0%) or pancreatic (22.9%) tumors, grade G1 (66.7%) or G2 (27.1%) with localized disease (31.3%), regional metastasis (16.7%) or distant metastasis (43.8%) at diagnosis, and 45.8% had clinical hormonal syndromes. MetS was defined according to Joint Interim Statement (JIS) criteria. Well-differentiated GEP-NETs were associated with MetS criteria as well as the individual components’ waist circumference, fasting triglycerides, and fasting plasma glucose (p = 0.003, p = 0.002, p = 0.011 and p < 0.001, respectively). The likelihood of the association was higher when the number of individual MetS components was greater than four. MetS and some individual MetS components including visceral obesity, dyslipidemia, and increased fasting glucose are associated with well-differentiated GEP-NET. This data provides a novel insight in unraveling the mechanisms leading to GEP-NET disease.
Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
Molecular Diversity Preservation International (MPDI)
2072-6694
20726694
shingle_catch_all_4 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Cancers doi: 10.3390/cancers10090293 Authors: Ana P. Santos Ana C. Santos Clara Castro Luís Raposo Sofia S. Pereira Isabel Torres Rui Henrique Helena Cardoso Mariana P. Monteiro The determinants for gastroenteropancreatic neuroendocrine tumors (GEP-NET) recent burden are matters of debate. Obesity and metabolic syndrome (MetS) are well established risks for several cancers even though no link with GEP-NETs was yet established. Our aim in this study was to investigate whether well-differentiated GEP-NETs were associated with obesity and MetS. Patients with well-differentiated GEP-NETs (n = 96) were cross-matched for age, gender, and district of residence with a control group (n = 96) derived from the general population in a case-control study. Patients presented gastro-intestinal (75.0%) or pancreatic (22.9%) tumors, grade G1 (66.7%) or G2 (27.1%) with localized disease (31.3%), regional metastasis (16.7%) or distant metastasis (43.8%) at diagnosis, and 45.8% had clinical hormonal syndromes. MetS was defined according to Joint Interim Statement (JIS) criteria. Well-differentiated GEP-NETs were associated with MetS criteria as well as the individual components’ waist circumference, fasting triglycerides, and fasting plasma glucose (p = 0.003, p = 0.002, p = 0.011 and p < 0.001, respectively). The likelihood of the association was higher when the number of individual MetS components was greater than four. MetS and some individual MetS components including visceral obesity, dyslipidemia, and increased fasting glucose are associated with well-differentiated GEP-NET. This data provides a novel insight in unraveling the mechanisms leading to GEP-NET disease.
Ana P. Santos; Ana C. Santos; Clara Castro; Luís Raposo; Sofia S. Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P. Monteiro
Molecular Diversity Preservation International (MPDI)
2072-6694
20726694
shingle_title_1 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
shingle_title_2 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
shingle_title_3 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
shingle_title_4 Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
timestamp 2025-06-30T23:36:36.252Z
titel Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
titel_suche Cancers, Vol. 10, Pages 293: Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
topic WW-YZ
uid ipn_articles_6324165